Christopher DeRenzo

Jan 6, 2025 | digitalcommons.library.tmc.edu | Meenakshi Hegde |Shoba Navai |Christopher DeRenzo |Sujith K. Joseph

Keywords Humans, Sarcoma, Middle Aged, Female, Male, Receptor, ErbB-2, Adult, Immunotherapy, Adoptive, Aged, Receptors, Chimeric Antigen, T-Lymphocytes, Lymphocyte Depletion, Prospective Studies, Vidarabine, Cyclophosphamide, Treatment Outcome Abstract In this prospective, interventional phase I study (NCT00902044) for patients with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T-cells (HER2-CART) after lymphodepletion with cyclophosphamide (Cy) +/−...